Novartis acquires biotech company with Greek roots for $1.7 billion
The acquisition of Regulus Therapeutics, a California-based biotechnology company focused on microRNA therapies, by Novartis for $1.7 billion was a major strategic move to expand the latter’s research portfolio in RNA technology.
- Published in Diaspora